^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ewing Sarcoma
    Regimen:IE (etoposide IV + ifosfamide)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    11/20/2020
    Excerpt:
    Ewing sarcoma: First-line therapy (primary/neoadjuvant/adjuvant therapy)…Preferred Regimens…VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide)
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    Summary of recommendations...Ewing Sarcoma...ChT regimens in relapse situations are not standardised and include alkylating agents (cyclophosphamide and high-dose ifosfamide) in combination with topoisomerase inhibitors (etoposide and topotecan), irinotecan with temozolomide [III, B] or gemcitabine and docetaxel, or high-dose ifosfamide or carboplatin with etoposide.
    DOI:
    10.1093/annonc/mdy310